Drugs MOA discusses the mechanism of action of each drug
Daratumumab Mechanism of Action: Daratumumab is a human monoclonal antibody. It is indicated for the treatment of Multiple Myeloma in the following situations: In Combination With … Daratumumab Indications Lenalidomide + dexamethasone Newly diagnosed Multiple Myeloma patients ineligible for autologous stem cell transplant OR Patients with relapsed or refractory multiple myeloma who have received at … Read more
Linzess MOA (Mechanism of action) is different from most other medications used to treat constipation and IBS (Irritable Bowel Syndrome) such as Miralax. Linzess (Linaclotide) is the first-in-class medicine that acts on the intestinal epithelial cells and stimulates the transmembrane Guanylate Cyclase 2C receptors (GC-2C). Activation of guanylate cyclase 2 C receptors results in the … Read more
Darolutamide MOA is discussed in this article. It is a recently approved chemotherapeutic drug for the treatment of prostate cancer. Drug Name: Darolutamide MOA Brand Name: Nubeqa The prostate is a prevalent malignancy that commonly affects elderly males. Most prostate cancers are responsive to hormones. A therapeutic objective is to impede their proliferation by inhibiting … Read more
Trofinetide MOA (Mechanism of action): Trofinetide is a synthetic peptide that has been developed as a potential treatment for Rett syndrome, a rare neurodevelopmental disorder that affects mainly girls. The mechanism of action of Trofinetide (Trofinetide MOA) is not fully understood, but it is believed to involve several different pathways in the brain. One of … Read more
Novartis’ Afinitor (everolimus) was approved by the FDA on February 26, 2016, for the treatment of adult patients with unresectable, locally advanced or metastatic progressive, well-differentiated non-functional neuroendocrine tumors (NETs) originating from the gastrointestinal or lung areas. Afinitor, also known as everolimus, is a type of medication categorized as an mTOR inhibitor. It is available … Read more
Tremelimumab is marketed by name, Imjudo. It is a CTLA-4 inhibitor that has been approved for the treatment of unresectable HCC and non-small-cell carcinoma. What is CTLA-4? CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a protein receptor that is expressed on the surface of T-cells (a type of immune cell). It functions as a negative regulator … Read more
Tysabri contains “Natalizumab” considered an evolution in the management of many autoimmune diseases. It is manufactured by Biogen Company and got FDA approval in 2004. In 2005 the drug was voluntarily withdrawn from the U.S. market when cases of progressive multifocal leukoencephalopathy were reported. However, it was again approved by FDA in 2006 due to … Read more
Tofacitinib is an oral Janus Kinase Inhibitor. Because of its unique and novel mechanism of action, it is one of the potent JAK Inhibitors. It was approved by the FDA in 2012. It is available in two formulations: Immediate Release as Xeljanz, and The Extended Release Oral Tablets as Xeljanz XR Tofacitinib is a Janus … Read more
Upadacitinib is among the novel class of medicines with a unique mechanism of action (MOA). It is available by the brand name, Rinvoq that has been approved in 2019 by the FDA. Among the biological medications, it is one of the few medicines that are available as oral tablet formulations with once-daily dosing. Rinvoq Indications: … Read more
Aimovig is a drug that is used in the preventive treatment of migraine headaches. It has got a unique mechanism of action. Aimovig is the brand name of Erenumab that is available as 70 mg/ml monthly subcutaneous injections. It is primarily indicated to prevent and reduce the severity of migraine headaches in patients who have … Read more